Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 310.00
Bid: 309.00
Ask: 310.00
Change: 10.00 (3.33%)
Spread: 1.00 (0.324%)
Open: 304.00
High: 316.00
Low: 304.00
Prev. Close: 300.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK TRADING UPDATE SUMMARY: Venture Life Sees Order Boost For Sanitiser

Tue, 09th Jun 2020 13:25

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Venture Life Group PLC - Berkshire-based self care products maker - Says order book "significantly ahead" of year prior. Reports solid demand for hand sanitiser gel product. Extends relationship with Alliance Pharma, becoming second manufacturer of Wiltshire-based pharmaceutical firm's Kelo-Cote scar gel products.

----------

Better Capital PCC Ltd - Guernsey-based investment company - To take write-down on valuation of investment in Everest, a British windows and home improvement firm. Better Capital's Fund II has invested GBP3.2 million into creation of Everest 2020, which bought assets of Everest Ltd, including its order pipeline. Pre-packaged administration deal rescued over 400 jobs at Everest and ensures existing orders can be completed.

----------

Plaza Centers NV - Netherlands-based property firm - Says buyer of company's stake in a shopping and entertainment centre in Belgrade will pay firm EUR830,000 to settle purchase. Plaza Centers to increase amount paid to bondholders to EUR500,000 from EUR250,000 at next payment date on July 1.

----------

Altyn PLC - gold miner in Kazakhstan - Says "positive momentum" continuing in second quarter with annualised monthly production run rate of 600,000 tonnes per year achieved in April and May. Altyn adds this represents 60% growth quarter-on-quarter. Altyn explains gold recovery grades also improved and beating budgeted targets. Seeing pick up in interest among investors, so far raised USD3.2 million out of USD10 million maximum in Astana Stock Exchange bond issue.

----------

Ormonde Mining PLC - Spain-focused natural resources - Cost-effective work programme at existing Spanish gold assets being advanced. Continuing to assess prospective projects, with 100 reviewed to date and a handful shortlisted "for further active consideration".

----------

Chaarat Gold Holdings Ltd - Gold miner in Armenia and Kyrgyz Republic - Targets 300,000 ounces per year production from 2026 at Kyzyltash deposit, Kyrgyz Republic. Lays out plans to get there, beginning with updated feasibility study in 2022, project financing in 2023 before construction follows in 2024 and 2025.

----------

Rockfire Resources PLC - Australia-focused gold and copper explorer - Reports results of 3D magnetic imagery at Plateau gold deposit in Lighthouse tenements, Australia. Probe confirms gold target beyond a depth of 600 metres. Field crew now in place to prepare for start of drilling.

----------

Star Phoenix Group Ltd - oilfield services firm in Trinidad - Yet to receive outstanding USD1.5 million payment from LandOcean Energy Services Co Ltd over sale of Range Resources Trinidad Ltd. Agreed deadline for payment was Monday and Star Phoenix has made "numerous attempts" to secure cash. Company now working with legal advisers.

----------

Destiny Pharma PLC - Brighton-based biotechnology firm - Awarded grant for research with Cardiff University to assess whether its DPD‑207, XF-70 and XF-73 drug compounds can treat fungal infections. Financial terms of partnership not disclosed.

----------

PureTech Health PLC - biotherapeutics firm based in Massachusetts - Reports "positive" data from founding company Vedanta Biosciences Inc's two Phase 1 studies of VE202 candidate for inflammatory bowel disease. Study shows VE202 was "safe and well-tolerated at all doses".

----------

Hutchison China Meditech Ltd - Hong Kong-based biopharmaceutical firm - Enters into agreement with Guangzhou government for planned return of Hutchison's remaining 34 years land-use rights of about 30,000 square meters of unused site. Hutchison will secure USD95 million for the return of the site.

----------

iEnergizer Ltd - Guernsey-based IT services firm - Reports strong performance in six months to March 31, its year end date. Says focus remained on high margin work and revenue set to be in line with market expectations but earnings before interest, taxes, depreciation and amortisation beating forecasts. Reaffirms commitment for progressive dividend policy.

----------

Redcentric PLC - London-based IT services provider - Extends loan facilities until June 30, 2022. Extended loan is a GBP17.5 million revolving credit facility provided by Barclays Bank PLC and National Westminster Bank PLC.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
28 Oct 2021 21:59

IN BRIEF: Hutchmed begins phase 3 trial of thrombocytopenia drug

IN BRIEF: Hutchmed begins phase 3 trial of thrombocytopenia drug

Read more
29 Sep 2021 11:08

Hutchmed China sells joint venture stake for USD169 million

Hutchmed China sells joint venture stake for USD169 million

Read more
21 Sep 2021 10:51

Hutchmed starts drug combination trial for neuroendocrine tumours

Hutchmed starts drug combination trial for neuroendocrine tumours

Read more
20 Sep 2021 09:09

Hutchmed starts Japan trial for surufatinib in neuroendocrine tumors

Hutchmed starts Japan trial for surufatinib in neuroendocrine tumors

Read more
13 Sep 2021 10:22

Hutchmed China's amdizalisib secures breakthrough therapy designation

Hutchmed China's amdizalisib secures breakthrough therapy designation

Read more
8 Sep 2021 13:49

Hutchmed, Astra launch drug combination trial to treat lung cancer

Hutchmed, Astra launch drug combination trial to treat lung cancer

Read more
6 Sep 2021 09:37

Hutchmed China to trade in Shanghai and Shenzhen through link scheme

Hutchmed China to trade in Shanghai and Shenzhen through link scheme

Read more
26 Aug 2021 10:38

Hutchmed launches trial into drug combination to treat breast cancer

Hutchmed launches trial into drug combination to treat breast cancer

Read more
9 Aug 2021 12:35

Hutchmed strikes collaboration deal with Epizyme

(Sharecast News) - Commercial-stage biotechnology company Hutchmed China announced a collaboration to research, develop, manufacture and commercialise 'Tazverik' in Greater China on Monday, including mainland China, Hong Kong, Macau and Taiwan.

Read more
9 Aug 2021 10:06

Hutchmed to partner with Epizyme on tumour-targetting treatment

Hutchmed to partner with Epizyme on tumour-targetting treatment

Read more
28 Jul 2021 14:51

Hutchmed research costs deepen loss; expects US launches in 2022, 2023

Hutchmed research costs deepen loss; expects US launches in 2022, 2023

Read more
28 Jul 2021 11:33

IN BRIEF: Hutchmed and AstraZeneca launch phase two cancer med trial

IN BRIEF: Hutchmed and AstraZeneca launch phase two cancer med trial

Read more
28 Jul 2021 10:58

AIM WINNERS & LOSERS: Hutchmed notes phase 2 trial; Tricorn drops 25%

AIM WINNERS & LOSERS: Hutchmed notes phase 2 trial; Tricorn drops 25%

Read more
21 Jul 2021 16:12

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
16 Jul 2021 11:19

AIM WINNERS & LOSERS: Pantheon up on resource upgrade, farmout talks

AIM WINNERS & LOSERS: Pantheon up on resource upgrade, farmout talks

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.